Pharma

GSK ESMO
Biotech

GSK sees phase 3 win for Hansoh-partnered ADC as justifying hype

Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs.
James Waldron Jul 10, 2026 8:39am
drawing of magnifying glass on a brain

GSK cuts losses on $700M upfront Alzheimer’s collab with Alector

Jul 9, 2026 7:30am
Duchenne muscular dystrophy DMD

Satellos’ ‘intriguing’ DMD data raise hopes ahead of key readout

Jul 8, 2026 9:48am
Deal

Scipher picks up Chemomab’s liver disease drug via merger

Jul 8, 2026 9:26am
AZ

AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre

Jul 8, 2026 5:00am
white hawk bird flying

Whitehawk swoops in for five ADCs via deal with Biocytogen

Jul 7, 2026 10:40am